Akeso has announced a significant milestone in its therapeutic pipeline with the National Medical Products Administration (NMPA) of China granting…
Read More
Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio
Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…
Read More
Johnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market
The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…
Read More
